Print Page   |   Contact Us   |   Sign In   |   Join Today
News & Press: General

Eyes on Washington: Federal Health Care Grant Notification Service

Monday, June 1, 2015   (0 Comments)
Posted by: TCAA Staff
Share |

Grant Opportunities for May 25, 2015 through May 29, 2015


Visit Holland & Knight online

  

New Federal Health Care Grant Opportunities Announced for:

·         Centers for Disease Control and Prevention (CDC)

·         Food and Drug Administration (FDA)

·         US Army Medical Research Acquisition Activity (USAMRAA)

·         National Institutes of Health (NIH)

 

NON-NIH Funding Opportunity Announcements:

 

CDC: Improving Immunization Collaboration Among Pharmacists and Other Healthcare Providers

Funding Opportunity Number: CDC-RFA-IP15-1504PPHF15

The purpose of this Funding Opportunity Announcement (FOA) is to demonstrate successful models of collaboration between pharmacists and other healthcare providers in a way that ensures up-to-date vaccination status of their shared patients. Stalled progress in raising some categories of immunization rates could be overcome if pharmacists and other healthcare providers could achieve a higher level of "immunization collaboration." Better collaboration between pharmacists and other healthcare providers is needed because of the increasing interdependence of pharmacists and other clinicians. Pharmacists are providing a higher percentage of immunization than in previous years. With that comes the need to strengthen their collaboration with other healthcare providers. This funding opportunity was announced on May 28, 2015. The application deadline is July 27, 2015. For more information, please visit CDC's Full Funding Opportunity Announcement.

 

FDA: Smokeless Tobacco Reference Products

Funding Opportunity Number: RFA-FD-15-026

This Funding Opportunity Announcement (FOA) solicits applications to develop a smokeless tobacco reference products program. The selected organization(s) will develop smokeless tobacco reference products representing at minimum two categories of commercially available smokeless tobacco product types to be used for investigational non-clinical purposes by tobacco manufacturers, contract and government laboratories, and academic institutions. The FDA will prioritize the product types. Development of this program will require significant collaboration and research efforts with outside organizations This funding opportunity was announced on May 26, 2015. The application deadline is July 31, 2015. For more information, please visit FDA's Full Funding Opportunity Announcement.

 

USAMRAA: Lung Cancer Concept Award

Funding Opportunity Number: W81XWH-15-LCRP-CA

The Lung Cancer Research Program (LCRP) Concept Award supports the exploration of a highly innovative new concept or untested theory that addresses an important problem relevant to lung cancer. The Concept Award is not intended to support an incremental progression of an already established research project but, instead, allows Principal Investigators (PIs) the opportunity to pursue serendipitous observations. This award mechanism supports high-risk studies that have the potential to reveal entirely new avenues for investigation. Submissions from and partnerships with investigators at military treatment facilities, military labs, and Department of Veterans Affairs (VA) medical centers and research laboratories are strongly encouraged. Military relevance will be considered in determining relevance to the mission of the LCRP during programmatic review. Investigators are strongly encouraged to consider the following characteristics as examples of how a project may demonstrate military relevance (1) use of military or Veteran populations or data in the proposed research, (2) collaboration with Department of Defense (DoD) or VA investigators, (3) involvement of military consultants (Army, Air Force) or specialty leaders (Navy, Marine Corps) to the Surgeons General in a relevant specialty area, (4) explanation of how the project addresses an aspect of lung cancer that has direct relevance to military Service members, Veterans, or other military health system beneficiaries. This funding opportunity was announced on May 26, 2015. The application deadline is August 11, 2015. For more information, please visit the Army's Full Funding Opportunity Announcement.

 

 

NIH Funding Opportunity Announcements:

 

NIH: Mucosal Immunology Studies Team

Funding Opportunity Number: RFA-AI-15-023

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications from institutions/organizations to participate in a cooperative research group, the Mucosal Immunology Studies Team (MIST), focusing on immune defense mechanisms and immune regulation at mucosal surfaces of the respiratory, gastrointestinal and urogenital tracts. The purpose of this funding opportunity is to break new ground in the understanding of basic mucosal immune defense mechanisms by introducing new ideas, approaches and technologies that address the difficult questions remaining in mucosal immunology. This funding opportunity was announced on May 26, 2015. A letter of intent is due by September 20, 2015. The application deadline is October 20, 2015. For more information, please visit FDA's Full Funding Opportunity Announcement.

 

NIH: Fast-Track Development of Medications to Treat Cannabis Use Disorders

Funding Opportunity Number: PAR-15-267

The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the discovery and development of medications to treat Cannabis Use Disorders (CUDs). The objective is to advance medications toward the ultimate goal of obtaining FDA approval. Advances in understanding the cannabinoid systems and the effects of marijuana on the brain, coupled with the availability of both novel and marketed medications that may be efficacious to treat these disorders, offer unprecedented opportunities to develop safe and effective pharmacotherapies for CUDs. This funding opportunity was announced on May 26, 2015. The initial application deadline is July 28, 2015. A letter of intent is due 30 days prior to the application deadline. For more information, please visit NIH's Full Funding Opportunity Announcement.

 

NIH: Collaborative Networks to Advance Delirium Research

Funding Opportunity Number: RFA-AG-16-009

This Funding Opportunity Announcement (FOA) is intended to support a collaborative network to advance scientific research on the causes, mechanisms, outcomes, diagnosis, prevention, and treatment of delirium in older adults. Delirium, defined as an acute impairment of cognition and attention, is a common complication of severe illness in older adults. It is associated with multiple adverse outcomes including increased morbidity, mortality, functional and cognitive decline, and institutionalization. Delirium remains markedly underdiagnosed. Moreover, the underlying mechanisms, and thereby potential treatment or prevention targets, are inadequately understood, as is prognosis. Addressing important research gaps may improve approaches for appropriate prevention and management, especially as studies of multicomponent interventions suggest that delirium may be at least 30-40% preventable. This funding opportunity was announced on May 27, 2015. A letter of intent is due by December 12, 2015. The application deadline is January 12, 2016. For more information, please visit NIH's Full Funding Opportunity Announcement.

 

NIH: Harnessing Genome Editing Technologies to Functionally Validate Genetic Variants in Substance Use Disorders

Funding Opportunity Number: RFA-DA-16-004

The purpose of this initiative is to harness genome or epigenome editing technologies to functionally validate and characterize genetic or epigenetic variants involved in substance use disorders. The genetic resources generated will be made broadly available to the scientific community to probe more deeply into the neurobiological mechanisms involved in the function of a variant, gene, or pathway and provide critical foundational knowledge for the development of future prevention, diagnostic, and therapeutic strategies. This funding opportunity was announced on May 27, 2015. A letter of intent is due by July 25, 2015. The application deadline is August 25, 2015. For more information, please visit NIH's Full Funding Opportunity Announcement.

 

NIH: Development and Testing of Novel Interventions to Improve HIV Prevention, Care, and Program Implementation

Funding Opportunity Number: PA-15-268

The purpose of this Funding Opportunity Announcement (FOA) is to support (1) pilot or feasibility studies of new or adapted interventions to prevent HIV infection among populations where substance use may be a contributing factor, (2) pilot or feasibility studies of new or adapted interventions to improve the care of HIV infection among populations where substance use is prevalent, including interventions that integrate treatment for substance use disorders and HIV infection, or (3) pilot or feasibility studies to increase the scale, uptake, delivery, and/or quality of HIV prevention or care interventions with established evidence of efficacy. Both primary and secondary prevention will be supported. The full range of substance use will be considered, including problematic episodic use and substance use disorders, as well as a full range of substances and modes of administration. The most important consideration is that substance use may affect transmission directly, as in the case of injection, or may affect transmission risk behavior. Domestic and overseas populations will be considered, with particular attention to populations with disproportionate burden of HIV infection and those where HIV infection and/or drug use are emergent. This funding opportunity was announced on May 28, 2015. The initial application deadline is November 16, 2016. For more information, please visit NIH's Full Funding Opportunity Announcement.


Association Management Software Powered by YourMembership  ::  Legal